Blood pressure, proteinuria and nephropathy in Fabry disease

Nephron - Clinical Practice

Volumn 118, Issue 1, 2010, Pages

  Jain, Gaurav ^a   Warnock, David G ^b  

^a UNIVERSITY OF ALABAMA   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Antiproteinuric therapy; Enzyme replacement therapy; Fabry disease; Hypertension; Proteinuria

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PROTEIN; ANTIHYPERTENSIVE AGENT; PLACEBO; RENIN INHIBITOR;

ALBUMINURIA; BLOOD PRESSURE; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG EFFICACY; ENZYME REPLACEMENT; FABRY DISEASE; FABRY NEPHROPATHY; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT INDICATION; TREATMENT OUTCOME; ANTIHYPERTENSIVE THERAPY; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; GLOMERULUS FILTRATION RATE; HEALTH SURVEY; HYPERKALEMIA; INDUCED HYPOTENSION; LOW DRUG DOSE; PATHOPHYSIOLOGY; PREVALENCE; PUBLICATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SIDE EFFECT; URINARY EXCRETION;

ADULT; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FABRY DISEASE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; PROTEINURIA;

EID: 78649290177     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320903     Document Type: Review

References (30)

1. Desnick RJ, Ioannou YA, Eng CM: Alphagalactosidase A deficiency: Fabry disease; in Scriver C, Beaudet A, Sly W, Valle D (eds): The Metabolic Bases of Inherited Disease. New York, McGraw-Hill, 2001, pp 3733-3774.
2. Eng CM, Fletcher J, Wilcox WR, Waldek S, Scott CR, Sillence DO, Breunig F, Charrow J, Germain DP, Nicholls K, Banikazemi M: Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007;30:184-192.
3. Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U, Sims K, Waldek S, Pastores GM, Lee P, Eng CM, Marodi L, Stanford KE, Breunig F, Wanner C, Warnock DG, Lemay RM, Germain DP: Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 2008;93:112-128.
4. Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C: Nephropathy in males and females with Fabry disease: crosssectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 2008;23:1600-1607.
5. Ortiz A, Cianciaruso B, Cizmarik M, Germain DP, Mignani R, Oliveira JP, Villalobos J, Vujkovac B, Waldek S, Wanner C, Warnock DG: End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol Dial Transplant 2010;25:769-775.
6. Desnick RJ: Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval. Expert Opin Biol Ther 2004;4:1167-1176.
7. Fervenza FC, Torra R, Warnock DG: Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease. Biologics 2008;2:1-22.
8. Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, Goldfarb L, Brady RO, Balow JE, Austin III HA, Kopp JB: Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002;81:122-138.
9. Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S, Sorensen SA, Wilcox WR, Desnick RJ: Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 2009;24:2102-2111.
10. Kleinert J, Dehout F, Schwarting A, de Lorenzo AG, Ricci R, Kampmann C, Beck M, Ramaswami U, Linhart A, Gal A, Houge G, Widmer U, Mehta A, Sunder-Plassmann G: Prevalence of uncontrolled hypertension in patients with Fabry disease. Am J Hypertens 2006;19:782-787. (Pubitemid 44107697)
11. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43:S1-S290.
12. Warnock DG: Enzyme replacement therapy and Fabry kidney disease: quo vadis? J Am Soc Nephrol 2007;18:1368-1370.
13. Schiffmann R: Enzyme replacement in Fabry disease: the essence is in the kidney. Ann Intern Med 2007;146:142-144.
14. Remuzzi G, Benigni A, Remuzzi A: Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006;116:288-296.
15. Schiffmann R, Askari H, Timmons M, Robinson C, Benko W, Brady RO, Ries M: Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol 2007;18:1576-1583.
16. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ: Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007;146:77-86.
17. Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, Wilcox WR, Guffon N: Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007;18:1547-1557.
18. Fogo A, Bostad L, Svarstad E, Cook WJ, Moll S, Barbey F, Geldenhuys L, West M, Ferluga D, Vujkovac B, Howie A, Burns A, Reeve R, Waldek S, Noel LH, Grunfeld JP, Valbuena C, Oliveira JP, Muller J, Breunig F, Zhang X, Warnock DG: Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant 2010;25:2168-2177.
19. Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP: Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004;75:65-74.
20. Whybra C, Miebach E, Mengel E, Gal A, Baron K, Beck M, Kampmann C: A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase-alfa in 36 women with Fabry disease. Genet Med 2009;11:441-449.
21. Mehta A, Beck M, Elliott P, Giugliani R, Linhart A, Sunder-Plassmann G, Schiffmann R, Barbey F, Ries M, Clarke JT: Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 2009;374:1986-1996.
22. Warnock DG, Daina E, Remuzzi G, West M: Enzyme replacement therapy and Fabry nephropathy. Clin J Am Soc Nephrol 2009;5:371-378.
23. Ruggenenti P, Schieppati A, Remuzzi G: Progression, remission, regression of chronic renal diseases. Lancet 2001;357:1601-1608.
24. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris GL: The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005;165:947-953.
25. Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D: Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RE-NAAL) trial. J Am Soc Nephrol 2007;18:1540-1546.
26. Tahir H, Jackson LL, Warnock DG: Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 2007;18:2609-2617.
27. Jain G, Campbell RC, Warnock DG: Mineralocorticoid receptor blockers and chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1685-1691.
28. Tahir H, Jackson LL, Warnock DG: Antiproteinuric therapy and Fabry nephropathy: sustained reduction in proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 2007;18:2609-2617.
29. ® and Arbs and ACE Inhibitor Treatment (FAACET) Study (NCT00446862), 2007.
30. Warnock DG, Daina E, Remuzzi G, West M: Enzyme replacement therapy and fabry nephropathy. Clin J Am Soc Nephrol 2010;5:371-378.